Pamela Lazar-Karsten

Ms. Pamela Lazar-Karsten


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ALAnna-Lena Lemster
Anna-Lena Lemster
ESElisabeth Sievers
Elisabeth Sievers
HPHelen Pasternack
Helen Pasternack
PLPamela Lazar-Karsten
Pamela Lazar-Karsten
NKNiklas Klümper
Niklas Klümper
Jutta KirfelJutta Kirfel
Jutta Kirfel
Prostate cancer (PCa) poses a major public health problem in men. Metastatic PCa is incurable, and ultimately threatens the life of many patients. Mutations in tumor suppressor genes and oncogenes are important for PCa progression, whereas the role of epigenetic factors in prostate carcinogenesis is insufficiently examined. The histone demethylase KDM5C exerts important roles in tumorigenesis. KDM5C has been reported to be highly expressed in various cancer cell types, particularly in primary PCa. Here, we could show that KDM5C is highly upregulated in metastatic PCa. Functionally, in KDM5C knockdown cells migratory and invasion capacity was reduced. Interestingly, modulation of KDM5C expression influences several EMT signaling pathways (e.g., Akt/mTOR), expression of EMT transcription factors, epigenetic modifiers, and miR-205, resulting in increased expression of E-cadherin and reduced expression of N-cadherin. Mouse xenografts of KDM5C knockdown cells showed reduced tumor growth. In addition, the Akt/mTOR pathway is one of the classic signaling pathways to mediate tumor metabolic homeostasis, which is beneficial for tumor growth and metastasis. Taken together, our findings indicate that a combination of a selective KDM5C- and Akt/mTOR-inhibitor might be a new promising therapeutic strategy to reduce metastatic burden in PCa.

23 July 2024 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
AGAndreas Gocht
Andreas Gocht
CHCarsten Heidel
Carsten Heidel
Jutta KirfelJutta Kirfel
Jutta Kirfel
RVRita Vesce
Rita Vesce
PLPamela Lazar-Karsten
Pamela Lazar-Karsten
VSVerena Sailer
Verena Sailer

21 April 2016 in Cells
Verified
Journal Article
Open access
PDF file
PLPamela Lazar-Karsten
Pamela Lazar-Karsten
GBGazanfer Belge
Gazanfer Belge
DSDetlev Schult-Badusche
Detlev Schult-Badusche
TFTim Focken
Tim Focken
ARArlo Radtke
Arlo Radtke
Salaheldien Ali Mohamed-GlueerSalaheldien Ali Mohamed-Glueer
Salaheldien Ali Mohamed-Glueer
Thoracic aortic dilation is the most common malformation of the proximal aorta and is responsible for 1%–2% of all deaths in industrialized countries. In approximately 50% of patients with a bicuspid aortic valve (BAV), dilation of any or all segments of the aorta occurs. BAV patients with aortic dilation show an increased incidence of cultured vascular smooth muscle cell (VSMC) loss. In this study, VSMC, isolated from the ascending aorta of BAV, was treated with Simian virus 40 to generate a BAV-originated VSMC cell line. To exclude any genomic DNA or cross-contamination, highly polymorphic short tandem repeats of the cells were profiled. The cells were then characterized using flow cytometry and karyotyping. The WG-59 cell line created is the first reported VSMC cell line isolated from a BAV patient. Using an RT2 Profiler PCR Array, genes within the TGFβ/BMP family that are dependent on losartan treatment were identified. Endoglin was found to be among the regulated genes and was downregulated in WG-59 cells following treatment with different losartan concentrations, when compared to untreated WG-59 cells.

20 September 2016 in Cells
Verified
Journal Article
Open access
PDF file
PLPamela Lazar-Karsten
Pamela Lazar-Karsten
GBGazanfer Belge
Gazanfer Belge
DSDetlev Schult-Badusche
Detlev Schult-Badusche
TFTim Focken
Tim Focken
ARArlo Radtke
Arlo Radtke
Salaheldien Ali Mohamed-GlueerSalaheldien Ali Mohamed-Glueer
Salaheldien Ali Mohamed-Glueer
The authors wish to make the following erratum to this paper [1].